Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 10/20 | 0.52 |
| ▸ | NPC1 | O15118 | 9/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 8/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308860 | 0.83 | HDAC1 (0.50) | KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL2311190 | 0.82 | MEN1 (0.54) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL2311822 | 0.81 | FKBP5 (0.48) | SMN1; SMN2MAPTRAB9ANPC1KMT2A | |
| SCHEMBL2313316 | 0.80 | JAK3 (0.47) | SMN1; SMN2RAB9ANPC1KMT2AHPGD | |
| SCHEMBL2309351 | 0.79 | GAA (0.50) | SMN1; SMN2RAB9AKMT2ATDP1LMNA | |
| SCHEMBL2312972 | 0.79 | JAK3 (0.46) | SMN1; SMN2MAPTRAB9ANPC1KMT2A | |
| SCHEMBL2312263 | 0.78 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTRAB9ANPC1KMT2A | |
| SCHEMBL2308410 | 0.78 | RAB9A (0.48) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL2313226 | 0.78 | PTPRC (0.44) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL2313546 | 0.77 | HTT (0.46) | SMN1; SMN2MAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011019618-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | SMN1; SMN2 3037/4885MAPT 3310/4885RAB9A 627/4885 |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | BTD, BAD, BRI3BP | SMN1; SMN2 3037/4885MAPT 3310/4885RAB9A 627/4885 |
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | SMN1; SMN2 3037/4885MAPT 3310/4885RAB9A 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.